Myriad Genetics (MYGN, Financial) experienced a significant 5.01% decline in its stock price. The stock now trades at $23.15 per share with a volume of 386,655 shares and a turnover rate of 0.43%, displaying a volatility of 4.54%.
In its latest financial report, Myriad Genetics reported revenue of $212 million, a net loss of $36.70 million, and an earnings per share of -$0.41. The company has a gross profit of $137 million, leading to a price-to-earnings ratio of -13.08. Among 16 institutions rating the stock, 44% recommend buying, 31% advise holding, and 25% suggest selling.
The life sciences sector, where Myriad Genetics operates, collectively saw a decline of 0.83%. Within this sector, Bioaffinity Technologies, Prenetics Global, and Caredx showed notable increases. Other active stocks include Applied DNA Sciences, Mainz Biomed, and Ispecimen, with turnover rates of 21.00%, 19.48%, and 10.06%, respectively. Stocks with significant volatility, such as Mainz Biomed, Volitionrx, and Ispecimen, presented amplitudes of 25.25%, 18.16%, and 11.41%.
Myriad Genetics is a molecular diagnostics company known for offering assessments of individuals' risk for various diseases. Their MyRisk test screens for elevated risks for 11 types of cancer through a 48-gene panel. Additional products include BRACAnalysis CDx, a companion diagnostic for PARP inhibitors approved by the FDA; GeneSight, which aids in enhancing responses to psychiatric medications for depression; and Prequel, a non-invasive prenatal screening. Launched in 2022, Precise Oncology Solutions integrates tumor-specific diagnostics with prognostic tests like MyChoice CDx, Prolaris, and EndoPredict, supporting pharmaceutical and biotech companies with biomarker discovery and companion diagnostics.
